Evoke Pharma Debt to Equity Ratio 2012-2024 | EVOK

Current and historical debt to equity ratio values for Evoke Pharma (EVOK) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Evoke Pharma debt/equity for the three months ending September 30, 2024 was 0.00.
Evoke Pharma Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-09-30 $0.01B $0.00B 2.23
2024-06-30 $0.01B $0.00B 3.55
2024-03-31 $0.01B $0.00B 2.56
2023-12-31 $0.01B $-0.00B -3.74
2023-09-30 $0.01B $-0.00B -9.99
2023-06-30 $0.01B $0.00B 15.68
2023-03-31 $0.01B $0.00B 3.72
2022-12-31 $0.01B $0.00B 1.90
2022-09-30 $0.01B $0.01B 1.42
2022-06-30 $0.01B $0.01B 1.00
2022-03-31 $0.01B $0.00B 3.67
2021-12-31 $0.01B $0.00B 1.97
2021-09-30 $0.01B $0.01B 1.44
2021-06-30 $0.01B $0.01B 1.94
2021-03-31 $0.01B $0.01B 1.47
2020-12-31 $0.01B $-0.00B -3.94
2020-09-30 $0.01B $-0.00B -4.51
2020-06-30 $0.01B $0.00B -23.12
2020-03-31 $0.00B $0.00B 0.59
2019-12-31 $0.00B $0.00B 0.46
2019-09-30 $0.00B $0.01B 0.42
2019-06-30 $0.00B $0.01B 0.20
2019-03-31 $0.00B $0.00B 0.42
2018-12-31 $0.00B $0.00B 0.41
2018-09-30 $0.00B $0.01B 0.30
2018-06-30 $0.00B $0.01B 0.24
2018-03-31 $0.00B $0.00B 0.27
2017-12-31 $0.01B $0.00B 2.67
2017-09-30 $0.01B $0.00B 4.22
2017-06-30 $0.01B $0.01B 0.94
2017-03-31 $0.01B $0.01B 0.87
2016-12-31 $0.01B $0.00B 1.45
2016-09-30 $0.01B $0.01B 1.30
2016-06-30 $0.01B $-0.00B -4.04
2016-03-31 $0.01B $0.00B 8.08
2015-12-31 $0.01B $0.00B 1.75
2015-09-30 $0.01B $0.01B 1.20
2015-06-30 $0.01B $0.00B 1.46
2015-03-31 $0.01B $0.01B 0.96
2014-12-31 $0.01B $0.01B 0.66
2014-09-30 $0.00B $0.01B 0.15
2014-06-30 $0.00B $0.02B 0.12
2014-03-31 $0.00B $0.02B 0.22
2013-12-31 $0.00B $0.02B 0.18
2013-09-30 $0.01B $0.02B 0.24
2013-06-30 $0.00B $-0.00B -1.83
2013-03-31 $0.00B $0.00B 0.00
2012-12-31 $0.00B 0.00
2012-09-30 $0.00B $0.00B 0.00
2012-06-30 $0.00B $0.00B 0.00
2011-12-31 $0.00B $0.00B 0.58
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.007B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Teligent (TLGT) United States $0.000B 0.00